NCT02535156View on ClinicalTrials.gov

Schizotypal Personality Disorder Risperidone

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2015

Conditions
Schizotypal Personality Disorder
Interventions
DRUG

Risperidone

1 mg Risperidone

DRUG

Placebo

Lactose Placebo

All Listed Sponsors
lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

NCT02535156 - Schizotypal Personality Disorder Risperidone | Biotech Hunter | Biotech Hunter